Kamada (KMDA) Other Non-Current Liabilities (2021 - 2026)
Kamada (KMDA) posted quarterly Other Non-Current Liabilities of $29.9 million for Q1 2026, down 9.29% year-on-year from $33.0 million in Q1 2025, and down 0.62% on a QoQ basis from $30.1 million in Q4 2025.
Kamada (KMDA) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Kamada (KMDA) has reported Other Non-Current Liabilities for 6 consecutive years, with $29.9 million the latest figure, recorded in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 9.29% year-over-year to $29.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.9 million (down 9.29% YoY) and the FY2025 annual result came in at $30.1 million, down 8.24% from the prior year.
- Other Non-Current Liabilities declined to $29.9 million in Q1 2026 per KMDA's latest filing, from $30.1 million in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for KMDA reached as high as $42.5 million in Q1 2022 and fell as low as $37280.0 in Q1 2023.
- A 5-year average of $30.8 million and a median of $34.1 million in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities sank 99.91% — and 2024, when it jumped 93360.3%.
- Year by year, Other Non-Current Liabilities stood at $37.3 million in 2022, then decreased by 7.85% to $34.4 million in 2023, then slipped by 4.55% to $32.8 million in 2024, then decreased by 8.24% to $30.1 million in 2025, then fell by 0.62% to $29.9 million in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $29.9 million, $30.1 million, and $32.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.93 Mn |
| Dec 31, 2025 | 30.11 Mn |
| Sep 30, 2025 | 32.54 Mn |
| Jun 30, 2025 | 32.78 Mn |
| Mar 31, 2025 | 32.99 Mn |
| Dec 31, 2024 | 32.82 Mn |
| Sep 30, 2024 | 34.12 Mn |
| Jun 30, 2024 | 34.24 Mn |
| Mar 31, 2024 | 34.84 Mn |
| Dec 31, 2023 | 34.38 Mn |
| Sep 30, 2023 | 36.48 Mn |
| Jun 30, 2023 | 36.51 Mn |
| Mar 31, 2023 | 37,280.00 |
| Dec 31, 2022 | 37.31 Mn |
| Sep 30, 2022 | 39,915.00 |
| Jun 30, 2022 | 41.30 Mn |
| Mar 31, 2022 | 42.53 Mn |
| Dec 31, 2021 | 43.93 Mn |